Argenx SE Logo
NL0010832176
A11602
ARGX.BR

Argenx SE

Kurser indlæses...

Prognose

Køb
  21
Behold
  3
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Argenx posts high Vyvgart revenues, operating result below analysts' expectations

    In the third quarter Argenx's revenue rose by over 50% year-on-year to $1.72 billion thanks to Vyvgart; operating income climbed to $486 million but missed the Bloomberg consensus. Net income attributable to shareholders was $506 million due to a tax effect. Higher R&D and commercialization costs and a recent trial termination in Sjögren’s weigh on the stock, which turned positive after initial losses. Argenx plans a label expansion for Vyvgart Hytrulo and a regulatory study in dermatomyositis; Efgartigimod Alfa remains the main source of revenue. » Mere på finanzen.net


  • arGEN-X: revenue boom driven by Vyvgart, earnings hit by higher R&D and sales expenses

    In the third quarter arGEN-X’s revenue rose by more than 50% to $1.72 billion, almost entirely driven by sales of the drug Vyvgart. Operating income grew 40% year-on-year to $486 million but fell short of analysts’ expectations. The main reasons for margin pressure are increased research and marketing costs. Net income attributable to shareholders was $506 million, up from $344 million a year earlier. CEO Karen Massey emphasizes that Vyvgart is the business foundation and that further growth opportunities exist. » Mere på finanzen.net


  • Argenx shares recover slightly after phase-III trial flop

    European stocks extended their recovery on Monday, supported by an agreement between Europe and China on export restrictions for hybrid cars, which could particularly benefit auto stocks. The EuroStoxx 50 rose 0.45 percent, the SMI gained 0.66 percent and the FTSE 100 climbed 0.99 percent. Argenx shares added 0.7 percent after having fallen sharply following the failure of a pivotal phase-III study. Ahold Delhaize fell nearly three percent after reports of IT problems and resulting security measures. » Mere på finanzen.net


  • Argenx stops phase-III study of Efgartigimod Sc in Sjögren – stock plunges

    Argenx has halted the advanced phase-III study of Efgartigimod Sc for the treatment of Sjögren’s syndrome, after which the share price fell by double digits. At the same time the biotech reported positive trial results for a potential celiac disease drug, but could not prevent the sell-off. » Mere på finanzen.net


  • Argenx halts UNITY study of Vyvgart — shares tumble 17%

    Argenx has stopped the late‑stage UNITY study seeking approval of Vyvgart for Sjögren’s syndrome on the recommendation of an independent data monitoring committee due to futility. The move removes a potential revenue source and is likely to materially reduce peak sales forecasts for Vyvgart; the stock fell about 17% on the news. At the same time, Argenx reported a positive result: the primary endpoint of a phase‑2 study of FB102 in celiac disease was met, but this is secondary in significance given the study halt. » Mere på deraktionaer.de

Virksomhedstal

I det seneste kvartal havde Argenx SE en omsætning på 1,52 mia. € og et nettoresultat på 446,72 mio. €
(EUR) september 2026
YoY
Omsætning 1,52 mia. -
Bruttofortjeneste 1,37 mia. -
Nettoresultat 446,72 mio. -
EBITDA 475,86 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
55,08 mia. €
Antal aktier
62,89 mio.
Højeste/laveste i 52 uger
925,79 € - 643,26 €
Udbytte Nej
Beta
-0,02
P/E (PE Ratio)
45,52
PEG (PEG Ratio)
2,38
K/I (PB Ratio)
7,22
P/S (PS Ratio)
13,60

Virksomhedsprofil

argenx SE er et bioteknologiselskab, der udvikler forskellige terapier til behandling af autoimmune sygdomme i USA, Holland, Belgien, Japan, Schweiz, Tyskland og Frankrig. Selskabets vigtigste produktkandidat er efgartigimod til behandling af patienter med myasthenia gravis, immun trombocytopeni, pemphigus vulgaris og kronisk inflammatorisk demyeliniserende polyneuropati i fase III-kliniske forsøg; bulløs pemphigoid og idiopatisk inflammatorisk myopati i fase II/III-kliniske forsøg; og ENHANZE SC i præklinisk undersøgelse. Virksomheden udvikler desuden immunologiske innovationsprogrammer, herunder cusatuzumab til hæmatologisk cancer samt høj-risiko MDS; ARGX-119, et antistof, der er rettet mod muskelspecifik tyrosinkinase-stadiet; ARGX-117 til alvorlige autoimmune indikationer; ARGX-118 til luftvejsinflammation; og ARGX-120 til behandling af autoimmune sygdomme. Derudover omfatter selskabets partnerede produktkandidater ARGX-115 til behandling af cancer; ARGX-112 til behandling af interleukin-22-receptoren; og ARGX-114, et antistof rettet mod MET-receptoren. Selskabet har en strategisk partnerskab med AbbVie S.À.R.L., Zai Lab Limited og LEO Pharma A/S samt en samarbejds- og licensaftale med Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V. og Shire International GmbH. argenx SE blev stiftet i 2008 og har hovedsæde i Breda, Holland.

Navn
Argenx SE
CEO
Karen Massey
Hjemsted Amsterdam, nh
Nederlandene
Websted
Sektor
Sundhed
Branche
Bioteknologi
Børsnotering
10.07.2014
Medarbejdere 1.863

Tickersymboler

Børs Symbol
Euronext
ARGX.BR
Pnk
ARGNF
Brussels Stock Exchange
ARGX.BR
Frankfurt
1AE.F
Düsseldorf
1AE.DU
London
0QW0.L
München
1AE.MU
Wien
ARGX.VI
🍪

Parqet  bruger cookies. Læs mere